Cutaneous T Cell Lymphoma Treatment

View All

emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment
How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle its Treatment Landscape

Cutaneous T-cell lymphoma (CTCLs) characterized by cutaneous infiltration of malignant monoclonal T-lymphocytes is a rare lymphoma affecting around 6.4 cases per million individuals every year. The total incident population of Cutaneous T-cell lymphoma in the 7MM was around 7.5K in 2021, with the US accounting for ...

Find More

Cutaneous T-cell Lymphoma Treatment Outlook
Insights Into The Cutaneous T-cell Lymphoma Treatment Market

Cutaneous T-cell lymphomas (CTCLs) constitute a group of non-Hodgkin lymphomas of the skin. CTCL has an annual age-adjusted incidence of approximately 6 cases per million people. In the United States, approximately 1,000 new cases of skin lymphoma are diagnosed each year. CTCL affects males twice as females. Moreov...

Find More

Pharma News
Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M

A biotech company Novome Biotechnologies is developing novel live medicines for chronic diseases, has raised USD 33 Million in Series A financing. The financing was led by DCVC Bio with participation from seed investor 5AM Ventures, Alta Partners, Alexandria Venture Investments and Mayo Clinic. The company plan...

Find More